221 related articles for article (PubMed ID: 32111235)
1. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.
Smith CG; Moser T; Mouliere F; Field-Rayner J; Eldridge M; Riediger AL; Chandrananda D; Heider K; Wan JCM; Warren AY; Morris J; Hudecova I; Cooper WN; Mitchell TJ; Gale D; Ruiz-Valdepenas A; Klatte T; Ursprung S; Sala E; Riddick ACP; Aho TF; Armitage JN; Perakis S; Pichler M; Seles M; Wcislo G; Welsh SJ; Matakidou A; Eisen T; Massie CE; Rosenfeld N; Heitzer E; Stewart GD
Genome Med; 2020 Feb; 12(1):23. PubMed ID: 32111235
[TBL] [Abstract][Full Text] [Related]
2. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
3. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
5. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy.
Park JS; Kim H; Jang WS; Kim J; Ham WS; Lee ST
Cancer Sci; 2024 May; 115(5):1680-1687. PubMed ID: 38475661
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.
Jiménez I; Chicard M; Colmet-Daage L; Clément N; Danzon A; Lapouble E; Pierron G; Bohec M; Baulande S; Berrebi D; Fréneaux P; Coulomb A; Galmiche-Rolland L; Sarnacki S; Audry G; Philippe-Chomette P; Brisse HJ; Doz F; Michon J; Delattre O; Schleiermacher G
Int J Cancer; 2019 Jan; 144(1):68-79. PubMed ID: 29923174
[TBL] [Abstract][Full Text] [Related]
7. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
9. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Yu H; Han L; Yuan J; Sun Y
Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
[TBL] [Abstract][Full Text] [Related]
11. KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer - an observational trial. Study protocol.
Iisager L; Ahrenfeldt J; Keller AK; Nielsen TK; Fristrup N; Lyskjær I
Acta Oncol; 2024 Feb; 63():51-55. PubMed ID: 38391290
[TBL] [Abstract][Full Text] [Related]
12. Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.
Ohta R; Yamada T; Sonoda H; Matsuda A; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yokoyama Y; Hara K; Yoshida H
Eur J Surg Oncol; 2021 Dec; 47(12):3151-3156. PubMed ID: 34315643
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
[TBL] [Abstract][Full Text] [Related]
15. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.
Kim YJ; Kang Y; Kim JS; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park D; Park WY; Kang M
Sci Rep; 2021 Mar; 11(1):5600. PubMed ID: 33692449
[TBL] [Abstract][Full Text] [Related]
16. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
[TBL] [Abstract][Full Text] [Related]
17. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
Zhang H; He B; Cui J; Zhao M; Zhang Z
Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
[TBL] [Abstract][Full Text] [Related]
19. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
